Drug Information

General Information
Drug ID
DR01403
Drug Name
Substance P
Synonyms
Substance P; 33507-63-0; Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2; CCRIS 7229; UNII-675VGV5J1D; EINECS 251-545-8; CHEMBL235363; 675VGV5J1D; 12769-48-1; P substance; Neurokinin P; Substanz-P; C63H98N18O13S; Substance P analogue; AC1Q5IQE; AC1L1VX3; tachykinin substance P (SP); SCHEMBL1116347; GTPL2098; ArgProLysProGlnGlnPhePheGlyLeuMet; MolPort-023-276-010; ADNPLDHMAVUMIW-CUZNLEPHSA-N; 2053AH; BDBM50001450; AKOS024456424; NCGC00167123-01; 11035-08-8; LS-147256; Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-amine
Drug Type
Small molecular drug
Indication Type 1 diabetes [ICD11: 5A10] Phase 1 [1]
Structure
3D MOL 2D MOL
Formula
C63H98N18O13S
Canonical SMILES
CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CNC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CCC(=O)N)NC(=O)C(CCC(=O)N)NC(=O)C3CCCN3C(=O)C(CCCCN)NC(=O)C4CCCN4C(=O)C(CCCN=C(N)N)N
InChI
InChI=1S/C63H98N18O13S/c1-37(2)33-45(57(89)74-41(53(68)85)27-32-95-3)73-52(84)36-72-54(86)46(34-38-15-6-4-7-16-38)78-58(90)47(35-39-17-8-5-9-18-39)79-56(88)42(23-25-50(66)82)75-55(87)43(24-26-51(67)83)76-59(91)49-22-14-31-81(49)62(94)44(20-10-11-28-64)77-60(92)48-21-13-30-80(48)61(93)40(65)19-12-29-71-63(69)70/h4-9,15-18,37,40-49H,10-14,19-36,64-65H2,1-3H3,(H2,66,82)(H2,67,83)(H2,68,85)(H,72,86)(H,73,84)(H,74,89)(H,75,87)(H,76,91)(H,77,92)(H,78,90)(H,79,88)(H4,69,70,71)/t40-,41-,42-,43-,44-,45-,46-,47-,48-,49-/m0/s1
InChIKey
ADNPLDHMAVUMIW-CUZNLEPHSA-N
CAS Number
CAS 33507-63-0
Pharmaceutical Properties Molecular Weight 1347.6 Topological Polar Surface Area 544
Heavy Atom Count 95 Rotatable Bond Count 42
Hydrogen Bond Donor Count 15 Hydrogen Bond Acceptor Count 17
XLogP
-2.3
PubChem CID
36511
PubChem SID
650627 , 14890642 , 34677952 , 50048187 , 50112420 , 77820088 , 103538528 , 103915915 , 104324228 , 117568894 , 134346412 , 134999114 , 135651888 , 137239514 , 137275539 , 162223926 , 227357862 , 241182181 , 241375257 , 249617258 , 252469376
TTD Drug ID
D0J8SU
DT(s) Transporting This Drug P-GP Transporter Info P-glycoprotein 1 Substrate [2]
References
1 ClinicalTrials.gov (NCT02820558) Neuropeptide Therapy of Recent Onset Type 1 Diabetes
2 Transport of somatostatin and substance P by human P-glycoprotein. FEBS Lett. 2004 Sep 10;574(1-3):55-61.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.